Amgen’s SWOT analysis: stock poised for growth amid challenges in obesity market

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with an overall "GOOD" financial health score according to InvestingPro, finds itself at a critical juncture as it navigates a competitive landscape while pursuing growth opportunities in key therapeutic areas. With a market capitalization of $149 billion and strong profitability metrics, including a 69% gross profit margin, this comprehensive analysis examines Amgen’s current position, recent financial performance, and future prospects, with a particular focus on its emerging obesity treatment, MariTide.

Company Overview and Recent Performance

Amgen has established itself as a prominent player in the biotechnology industry, with a diverse portfolio of products spanning areas such as cardiovascular disease, oncology, and bone health. The company’s recent financial performance has been solid, with Q1 2025 results exceeding expectations. Revenues reached $9.09 billion, surpassing the FactSet consensus of $8.88 billion, while earnings per share (EPS) of $5.31 beat the consensus estimate of $5.08. Based on InvestingPro data, the company’s revenue growth stands at 15.6% over the last twelve months, with net income expected to grow further this year.

Looking ahead, Amgen has provided guidance for 2025 that suggests continued growth. The company projects revenues between $34.3 billion and $35.7 billion, representing a year-over-year increase of approximately 5%. Non-GAAP EPS is expected to range from $20.00 to $21.20, indicating growth of about 4% compared to the previous year. According to InvestingPro analysis, the stock is currently trading at a P/E ratio of 25.2, which appears favorable relative to its near-term earnings growth potential. The company’s strong free cash flow yield and consistent dividend growth history of 14 consecutive years further support its financial stability.

Product Portfolio and Pipeline

Amgen’s current product lineup includes several key performers that continue to drive growth. Repatha, a cholesterol-lowering medication, has shown strong volume growth of 41% in recent quarters, highlighting its importance to Amgen’s stable business. The company’s bone health franchise, including Evenity and Prolia, has also demonstrated robust performance.

In the biosimilars segment, Amgen has made significant strides. Pavblu, a biosimilar for Eylea, generated $99 million in revenue during its first quarter on the market. This strong performance was attributed in part to reduced funding for patient assistance charities for branded anti-VEGF agents.

MariTide: A Potential Game-Changer in Obesity Treatment

One of the most closely watched developments in Amgen’s pipeline is MariTide, an ultra-long-acting self-injectable medication for weight control and cardiometabolic health. The company recently presented 52-week Phase 2 data showing significant weight loss in obese patients, and has initiated the Phase 3 MARITIME program.

Analysts are divided on MariTide’s potential market impact. Some express confidence in the quality of its weight loss and cardiometabolic data, suggesting it could play a significant role in the market, particularly among more severely obese patients managed by specialists. Others raise concerns about its competitive positioning given the rapid advancements by competitors in the field.

Competitive Landscape and Market Challenges

Amgen faces intense competition in the diabetes and obesity treatment space. Lilly’s oral GLP-1 agonist orforglipron has shown positive Phase III results, potentially challenging MariTide’s market position. The debate among experts centers not on the efficacy of MariTide’s data, but rather on its role in the market compared to daily oral options.

Despite these challenges, some analysts believe that MariTide’s ultra-long-acting, self-injected modality could still carve out a significant niche, especially among patients seeking rapid and durable weight loss along with improvements in cardiometabolic parameters.

Future Outlook and Growth Drivers

Amgen’s future growth prospects appear promising, driven by a combination of established products and pipeline developments. The company’s cardiometabolic franchise is expected to entrench and expand, contributing to overall growth. Additionally, Amgen’s focus on biosimilars could provide a substantial revenue stream in the coming years.

Several upcoming catalysts could influence investor sentiment in 2025. These include Phase 3 data for MariTide, Phase 2 obesity and Type 2 diabetes mellitus study results expected at the American Diabetes Association meeting in June, and potential advancements in other pipeline assets such as Rocatinlimab, Uplizna, and Bemarituzumab.

Bear Case

How will competition from oral GLP-1 agonists impact MariTide’s market potential?

The emergence of oral GLP-1 agonists, such as Lilly’s orforglipron, presents a significant challenge to MariTide’s market prospects. These oral medications offer the convenience of daily dosing without the need for injections, which could be more appealing to many patients. The positive Phase III results from orforglipron demonstrate that oral options can provide effective weight loss and glycemic control, potentially limiting the addressable market for injectable treatments like MariTide.

Moreover, the rapid advancements in the field of obesity and diabetes treatments mean that MariTide’s once-monthly dosing and mechanism of action may not be sufficiently compelling to differentiate it from competitors. This could lead to challenges in gaining market share and achieving peak sales estimates, especially if oral options continue to show strong efficacy and safety profiles.

Can Amgen maintain growth in mature products like Repatha?

While Repatha has shown strong volume growth recently, there are concerns about its long-term sustainability. As a mature product in the cholesterol-lowering market, Repatha faces potential challenges from biosimilar competition and pricing pressures. The cardiovascular disease treatment landscape is evolving rapidly, and new innovative therapies could emerge that may impact Repatha’s market position.

Additionally, as healthcare systems globally continue to focus on cost containment, there may be increased scrutiny on the cost-effectiveness of treatments like Repatha. This could lead to reimbursement challenges or pressure to lower prices, potentially impacting Amgen’s revenue growth from this key product.

Bull Case

How might MariTide’s unique features differentiate it in the obesity market?

Despite the competition from oral GLP-1 agonists, MariTide’s ultra-long-acting, self-injectable formulation could offer distinct advantages in the obesity treatment market. Its once-monthly dosing regimen may appeal to patients who struggle with daily medication adherence or prefer less frequent interventions. This could be particularly attractive for severely obese patients under specialist care, who may benefit from a more intensive treatment approach.

Furthermore, MariTide’s mechanism of action as a bispecific GLP-1 agonist/GIP antagonist could potentially offer superior efficacy or a unique metabolic profile compared to single-target therapies. If the Phase 3 MARITIME trial demonstrates improved tolerability with the planned 3-step titration protocol, it could address the concerns about side effects seen in earlier studies and strengthen MariTide’s competitive position.

What potential does Amgen’s biosimilar portfolio have for driving future growth?

Amgen’s expanding biosimilar portfolio represents a significant opportunity for future growth. The strong performance of Pavblu, the Eylea biosimilar, demonstrates the company’s ability to successfully enter and compete in the biosimilar market. As more biologics lose patent protection in the coming years, Amgen is well-positioned to leverage its expertise in developing and commercializing biosimilars.

The biosimilars market is expected to grow substantially as healthcare systems seek cost-effective alternatives to expensive branded biologics. Amgen’s established presence in this space, combined with its robust development pipeline, could lead to a steady stream of new biosimilar launches. This diversification of revenue sources could help offset potential declines in mature products and provide a more stable growth trajectory for the company.

SWOT Analysis

Strengths:

• Diverse and strong product portfolio across multiple therapeutic areas
• Robust pipeline with potential blockbuster candidates like MariTide
• Growing presence in the biosimilars market
• Strong financial performance and consistent revenue growth

Weaknesses:

• Dependence on mature products facing potential biosimilar competition
• Clinical hold on AMG 513, potentially slowing down early-stage obesity program
• Challenges in differentiating new products in highly competitive markets

Opportunities:

• Significant market potential for MariTide in the growing obesity treatment space
• Expansion of biosimilar portfolio to capture market share from off-patent biologics
• Potential for pipeline assets to address unmet medical needs in various therapeutic areas

Threats:

• Intense competition in the diabetes and obesity treatment market
• Potential for biosimilar competition against key Amgen products
• Regulatory and pricing pressures in major markets
• Rapid technological advancements potentially disrupting current treatment paradigms

Analysts Targets

• Cantor Fitzgerald: $305 (June 24th, 2025)
• Piper Sandler: $329 (May 5th, 2025)
• BMO Capital Markets: $346 (May 2nd, 2025)
• RBC Capital Markets: $320 (February 5th, 2025)

Amgen finds itself in a position of both opportunity and challenge as it navigates the competitive biopharmaceutical landscape. While the company’s diverse product portfolio and promising pipeline offer significant growth potential, it must contend with intense competition and evolving market dynamics. The success of MariTide in the obesity market and the continued expansion of its biosimilar portfolio will be critical factors in determining Amgen’s future trajectory. Investors and industry observers will be closely watching the upcoming data readouts and regulatory milestones that could shape the company’s prospects in the coming years.

This analysis is based on information available up to June 24, 2025.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on AMGN. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore AMGN’s full potential at InvestingPro.

Should you invest in AMGN right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if AMGN is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate AMGN further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if AMGN appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.